A frenzy of innovation in obesity drugs is under way
Novo Nordisk and Eli Lilly are printing money now. But they will not be a stagnant duopoly
Source: livemint.com
📰 Sciwind Biosciences News
Sciwind Biosciences News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Sciwind Biosciences. Real-time updates on events, politics, business and more.
Pharma's big push for a new generation of obesity drugs
Rivals to Novo Nordisk and Eli Lilly are piling in | Business
Source: economist.com
Global Obesity Market Analysis Report 2023-2029: Shifting
Dublin, Aug. 24, 2023 (GLOBE NEWSWIRE) -- The "Global Obesity Market (2023 Edition) - Analysis By Drug Type (Appetite Suppressants, Combination Drugs,...
Source: globenewswire.com
Global Obesity Market Report 2023-2029: From Awareness Gap to Market Growth - Education and Diet Drive Obesity Market
/PRNewswire/ -- The "Global Obesity Market (2023 Edition) - Analysis By Drug Type (Appetite Suppressants, Combination Drugs, Malabsorption Drugs, Others), Age...
Source: prnewswire.com
Global Obesity Market Report 2023-2029: From Awareness Gap to Market Growth - Education and Diet Drive Obesity Market
The "Global Obesity Market (2023 Edition) - Analysis By Drug Type (Appetite Suppressants, Combination Drugs, Malabsorption Drugs, Others), Age Group, By Gender, By Region, By Country: Drivers, Trends and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
Source: yahoo.com
Weight loss treatments are about to explode — The names investors need to know
More than two-thirds of U.S. adults have obesity or are overweight. That means several weight loss drugs can be successful. A look at the landscape.
Source: cnbc.com
IPO Update: Structure Therapeutics Readies $125 Million IPO (Pending:GPCR)
Structure Therapeutics has filed proposed terms for a $125 million IPO. Click here to see why Im on Hold for the GPCR IPO.
United States Raymond Stevens Sciwind Biosciences Scripps Research Institute Company Pipeline Eli Lilly Company
Source: seekingalpha.com
Sciwind Biosciences Announces Positive Interim Results from Ongoing Phase 2b Clinical Trial of XW003 (Ecnoglutide) in Patients with Obesity
/PRNewswire/ -- Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic...
New Zealand Mohammed Junaidi Prnewswire Sciwind Biosciences Sciwind Biosciences Thai Pan Clinical Research At Sciwind
Source: prnewswire.com
Sciwind Biosciences and SynerK Enter into Research Partnership to Discover and Develop Novel siRNA Therapeutics
/PRNewswire/ -- Sciwind Biosciences, a clinical-stage biopharmaceutical company focused on discovering and developing innovative therapies to treat metabolic...
Source: prnewswire.com
Sciwind, SynerK to develop novel therapeutics for liver and metabolic diseases
Under the deal, both entities will focus on discovering and developing new therapeutics based on small interfering RNA (siRNA) technology. The partnership will identify new therapeutic targets, which are